Glenmark becomes the first company to launch fixed dose combination for Type 2 Diabetes

Glenmark becomes the first company to launch fixed dose combination for Type 2 Diabetes

Sodium Glucose Co-Transporter Inhibitor (SGLT2i) Remogliflozin Etabonate, a newly developed, patent-protected drug, has been introduced by Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company, in a fixed dose combination (FDC) with Vildagliptin, a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) (first-line medication for the treatment of type 2 diabetes). Type 2 diabetes should be managed with this set medication combination. In order to enhance glycemic control, patients must take the combination of Remogliflozin (100 mg) + Vildagliptin (50 mg) + Metformin (500/1000 mg) twice day. Remo MV and Remozen MV are two new brands introduced by Glenmark.

Remogliflozin + Vildagliptin + Metformin fixed dose combination (FDC) was launched by Glenmark as the world's first FDC and is now available in India. In the latter part of September 2021, Glenmark gained authorisation from the DCGI (India's drug approval authority) to manufacture and market this fixed dose combination.

Type 2 diabetes is increasingly being treated with SGLT2 inhibitors and DPP4 inhibitors around the world. Providing patients with diabetes in India with low-cost access to the latest treatments has been a goal of Glenmark's for some time.

An intriguing fixed dosage combination for addressing Type 2 diabetes that addresses much of the pathophysiology is Glenmark's FDC of Remogliflozin, Vildagliptin, and Metformin. AACE guidelines encourage the early use of mono components of the FDC in the anti diabetic medicine hierarchy for the management of Type 2 diabetes. Furthermore, the US FDA considers the FDC of SGLT2i + DPP4i + Metformin to be the first and only triple medication FDC that makes sense for approval.

Patients with long-term conditions like Type 2 diabetes must take various anti-diabetic medications for a long time. Furthermore, in India, patients are responsible for paying for their own medication, making the cost of medication a significant factor in treatment adherence. Glenmark's Remogliflozin + Vildagiptin + Metformin combination has been launched at a breakthrough price of Rs. 16.50 per tablet, to be taken twice daily; this amounts to Rs. 33.00 as the daily cost of therapy. While the average daily cost of therapy of existing brands in the same drug category (when clubbed together for price comparison) is around Rs 75, Compared to other available SGLT2 & DPP4 combo medicines administered with Metformin in India, this one costs about 53% less.

A world-class and well-researched combination medicine will be available at a reasonable price for patients in India thanks to Glenmark's Remogliflozin + Vildagliptin + Metformin combo. For adults with Type 2 diabetes, the DCGI, India's drug regulator, has approved this combination for use when metformin and one of the mono-components of a fixed dose combination do not provide adequate glycemic control, or when being treated with separate doses of Remogliflozin, Vildagliptin and Metformin.

"SGLT2i + DPP4i + Metformin FDCs are becoming the treatment of choice for type 2 diabetes management around the world. Glenmark has a particular interest in diabetes, and we have been in the forefront of providing Indian diabetics with access to cutting-edge treatment alternatives. To introduce this cutting-edge fixed dose combination to Indian patients with uncontrolled Type 2 diabetes that has undergone extensive research while remaining affordable, we are proud to say that Mr. Alok Malik, Group Vice President & Business Head, India Formulations, says it will improve patient compliance while providing glycemic and extra-glycemic benefits.